方法：对51例96眼甲状腺相关眼病患者以甲基强的松龙500mg静滴，连用3d； 后改用奥曲肽0.1mg球后注射1次，连续注射3次。疗程结束后1，3mo随访观察记录患者自觉症状及眼部体征。

结果：患者49例症状均有明显改善或消失。治疗后患眼平均眼球突出度下降3.1±1.4mm，睑裂高度下降2.4±0.9mm ，治疗前后差异均有统计学意义(P<0.05)。

结论：激素冲击联合奥曲肽球后注射治疗甲状腺相关眼病效果明显，不良反应小，安全可靠。

METHODS:Fifty-one cases(96 eyes)with thyroid associated ophthalmopathy were treated with methylprednisolone(500mg/d)for 3d, and then retrobulbar injection of octreotide(0.1mg/mo)for 3mo in one course. Symptoms and signs of the patients were observed before and after the treatment course.

RESULTS: Symptoms of 49 cases were improved significantly. In all cases, the mean value of exophthalmus of the patients was significantly decreased after the treatment by 3.1±1.4mm. The height of palpebral fissure was significantly decreased after the treatment by 2.4±0.9mm, there were statistically significant difference before and after treatment(P<0.05).

COCLUSION:Methylprednisolone with octreotide retrobulbar injection therapy can improve symptoms and signs of the patients with thyroid associated ophthalmopathy with high safety and no obvious side effect.